World Market for Personalized Medicine Diagnostics (Biomarkers, Pharmacodiagnostics, Tumor Assays, Cardiac Risk and Other Testing)
In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry.
The concept of 'Personalized Medicine', as seen by Kalorama clinical diagnostics industry analyst Shara Rosen, is currently somewhere between dream and road to reality. Fantastic promises have been made over the years in the press and reports of startup concerns. However, slowly but surely real revenues are appearing, and realistic models for future growth will be seen.
Developments that are linked in the press to 'personalized medicine' are many, and can at times be confusing. But there are several discovered biomarkers that are important in diagnostic markets.
Biomarkers discussed in the report include:
The concept of 'Personalized Medicine', as seen by Kalorama clinical diagnostics industry analyst Shara Rosen, is currently somewhere between dream and road to reality. Fantastic promises have been made over the years in the press and reports of startup concerns. However, slowly but surely real revenues are appearing, and realistic models for future growth will be seen.
Developments that are linked in the press to 'personalized medicine' are many, and can at times be confusing. But there are several discovered biomarkers that are important in diagnostic markets.
Biomarkers discussed in the report include:
- Cytochrome P450 and Drug Metabolism
- Estrogen Receptor and Progesterone
- Receptor Status for Breast Cancer
- HER2 Overexpression and Herceptin and Tykerb
- Epidermal Growth Factor Receptor (EGFR)
- KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
- BRAF Mutations and Cancer Therapy
- UGT1A1 Genetic Variants
- 5-Flurouracil Therapy
- PIK3CA Genetic Variation
- KIF6 Genetic Variation
- ALK Genetic Variation
- Cardiac Markers, immunoassays
- Cardiac Risk Markers
- Cardiac markers, molecular
- Coagulation, routine
- Coagulation, molecular
- Cancer, Tumor Markers
- Cancer, Molecular
- Cancer, Tissue-based
- Psychiatric Disorders
- Diabetes, BGM
- Diabetes, HbA1c
- Microbiology, ID/AST
- Infectious Diseases, Viral Load (HIV, HCV, HBV)
- Infectious Diseases, other
- Blood Bank Molecular
- Transplant Tissue Typing
- Lab Developed Tests
CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Size and Growth of the Market
Market Trends
CHAPTER TWO: INTRODUCTION
Background
Developments since 2000 - Limitations of Personalized Medicine and Future Prospects
Personalizing risk and therapies
Personalized Therapies - drugs, vaccines and others
Aspects of Personalized Medicine
Screening for Disease Risk
Early diagnosis
Therapy Selection and Monitoring
CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”
Background
Reimbursement of Novel Tests
United States
Europe
Payor Perspectives and Policies
Regulatory Issues and Personalized Medicine Assays
United States
Europe
IVD vs CLIA or Both
Physician Education and Acceptance
Patent Issues and Commercializing Personalized Diagnostics
Prospects for POC Testing
CHAPTER FOUR: DISEASE TARGETS
Background
Biomarker Validation and Utility
Cytochrome P450 and Drug Metabolism
Estrogen Receptor and Progesterone Receptor Status for Breast Cancer
HER2 Overexpression and Herceptin and Tykerb
Epidermal Growth Factor Receptor (EGFR)
KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
BRAF Mutations and Cancer Therapy
UGT1A1 Genetic Variants
5-Flurouracil Therapy
PIK3CA Genetic Variation
KIF6 Genetic Variation
ALK Genetic Variation
CHAPTER FIVE: DIAGNOSTIC PRODUCTS
PCR-based assays
Single nucleotide polymorphism (SNP) genotyping
Next-gen sequencing
LDTs reign
Miniaturization and Multiplexed Assays
Multi-Gene/Biomarker Tests in Oncology
Mass Spectroscopy
Role of Nanobiotechnology
Proteomics and Biomarker Detection
Molecular Imaging and Personalized Medicine
Information Technology
CHAPTER SIX: MARKET ANALYSIS
Background
Worldwide Opportunities for Personalized Medicine Diagnostics
The United States
Europe
Japan
ROW
Agreements between Pharmaceutical and Diagnostic Companies
Agreements between IVD companies and CLIA labs
Major Companies and Labs
The Market for Personalized Medicine in Cancer Management
Tissue-based Tests
Blood Markers
Circulating Tumor Cells
The Market for Personalized Medicine in Infectious Diseases
HIV
HBV
HCV
Hospital Acquired Infections
The Market for Personalized Medicine in Coagulation Therapy
Warfarin
Platelet Function
The Market for Personalized Medicine in Autoimmune Diseases
The Market for Personalized Medicine in Cardiovascular Diseases
The Market for Personalized Medicine in CNS Disorders
The Market for Personalized Medicine in Diabetes
The Market for Personalized Medicine in Blood Transfusion Safety
The Market for Personalized Medicine in Nutrition and Beauty
CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
CHAPTER EIGHT: COMPANY PROFILES
The Major IVD Companies
Abbott Diagnostics Beckman Coulter Inc. Becton, Dickinson and Company
bioMérieux Inc.
Celera Corporation
Cepheid
China Medical Technologies
Dako Denmark A/S
Fujirebio Diagnostics, Inc.
GE Healthcare
Gen-Probe Inc.
Immucor, Inc.
Luminex Corporation
PerkinElmer Inc.
Phadia AB
QIAGEN N.V.
Roche Diagnostics
Siemens Healthcare Diagnostics
Ventana Medical Systems Inc.
Wako Diagnostics
Participants
20/20 GeneSystems, Inc.
23andMe
Accumetrics
AdvanDx, Inc.
Affymetrix, Inc.
Agendia BV
Almac Diagnostics
AltheaDx, Inc.
Ambry Genetics
Arrayit Corporation
ARUP Laboratories
AssureRx Health, Inc.
Asuragen, Inc.
Autogenomics Inc.
BG Medicine, Inc.
Biocare Medical, LLC
Biocartis SA
Biocept, Inc.
BioCurex, Inc.
Biodesix, Inc.
BioReference Laboratories, Inc.
BioServe
bioTheranostics
Clarient Inc.
CombiMatrix Molecular Diagnostics, Inc.
Corgenix Medical Corporation
Cylex, Inc.
Dana Farber Cancer Institute
DeCode Genetics
DxS Ltd.
DxTerity Diagnostics Inc.
Enzo Clinical Labs
Epigenomics AG
Euroimmun AG
Genelex Corporation
Genomic Health, Inc.
Genoptix Medical Laboratory
Genzyme Genetics
Illumina Inc.
Interleukin Genetics, Inc.
Ipsogen SA
Knome, Inc.
Lab21 Limited
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies Corporation
Mayo Medical Laboratories
MDxHealth SA
Monogram Biosciences, Inc.
Myriad Genetics, Inc.
Nanosphere, Inc.
Navigenics
Pathway Genomics
Pathwork Diagnostics, Inc.
Power3 Medical Products, Inc.
Precision Therapeutics
Predictive Biosciences
Progenika Inc.
Prometheus Laboratories Inc.
Quest Diagnostics Incorporated
Response Genetics, Inc.
Rosetta Genomics
Rules-Based Medicine, Inc.
Saladax Biomedical, Inc.
Sequenom, Inc.
TGen (The Translational Genomics Research Institute)
TrimGen Corporation
TrovaGene, Inc.
Veridex, LLC
Vermillion Inc.
Virco BVBA
XDx, Inc.
The Newcomers
Abkine Pharmaceuticals
Accelerated Medical Diagnostics, LLC
Advanced Biological Laboratories
Affomix Corporation
Ahram Biosystems, Inc.
Alacris Theranostics GmbH
Amoy Diagnostics Co. Ltd.
ApoCell, Inc.
Atossa Genetics, Inc.
Augurex Life Sciences Corp.
Biofortuna Ltd.
Biomarker Factory, The
BioMarker Strategies
Biomedical Diagnostics
BlackBio S.L.
Bostwick Laboratories
Cancer Genetics, Inc.
Cancer Treatment Centers of America
CancerGuide Diagnostics, Inc.
CardioDx, Inc.
Caris Life Sciences
Chronix Biomedical
Crescendo Bioscience, Inc.
Critical Diagnostics
Curidium Medica Limited
CvergenX
DermaGenoma, Inc.
DiaTech Oncology
Eutropics Pharmaceuticals
Everist Genomics
Evotec AG
Exosome Diagnostics Inc.
Foundation Medicine Inc.
GeneNews Limited
Genetic Technologies Limited
GenMark Diagnostics Inc.
Genomas
Genomind, LLC
GenoVive LLC
GMS Biotech
Inostics GmbH
Insight Genetics
IntegraGen SA
IRIS International, Inc.
Iverson Genetic Diagnostics, Inc.
Linkage Biosciences, Inc.
Med BioGene, Inc.
Medco Health Solutions Inc.
Metamark Genetics, Inc.
Mira Dx
Molecular Response
MolecularMD Corp.
Nanostring Technologies, Inc.
NaturalNano, Inc.
NewGene
NobleGen Biosciences
Nodality Inc.
Novartis Molecular Diagnostics
Nuvera Biosciences, Inc.
On-Q-ity
Orion Genomics
OvaGene Oncology, Inc.
Pacific Edge Biotechnology Limited
Pathogenica
Pharmigene
Pinpoint Genomics, Inc.
Population Diagnostics, Inc.
Proctor & Gamble
Psynomics Incorporated
Radient Pharmaceuticals Corporation
ScreenCell
Scripps Health
Seegene Inc.
Signal Genetics
Signature Diagnostics AG
Sirius Genomics
Skyline Diagnostics B.V.
Spartan Bioscience Inc.
SureGene, LLC
TcLand Expression SA
Transgenomic, Inc.
ViennaLab Diagnostics GmbH
Information Technology Specialists
CLC bio
CollabRx
Definiens
Dell Healthcare and Life Sciences
DNA Direct
GenomeQuest Inc.
HolGenTech Inc.
IDBS
MediSapiens Ltd.
Partners HealthCare Center for Personalized Genetic Medicine
Selventa
Sophic Systems Alliance
Introduction
Scope and Methodology
Size and Growth of the Market
Market Trends
CHAPTER TWO: INTRODUCTION
Background
Developments since 2000 - Limitations of Personalized Medicine and Future Prospects
Personalizing risk and therapies
Personalized Therapies - drugs, vaccines and others
Aspects of Personalized Medicine
Screening for Disease Risk
Early diagnosis
Therapy Selection and Monitoring
CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”
Background
Reimbursement of Novel Tests
United States
Europe
Payor Perspectives and Policies
Regulatory Issues and Personalized Medicine Assays
United States
Europe
IVD vs CLIA or Both
Physician Education and Acceptance
Patent Issues and Commercializing Personalized Diagnostics
Prospects for POC Testing
CHAPTER FOUR: DISEASE TARGETS
Background
Biomarker Validation and Utility
Cytochrome P450 and Drug Metabolism
Estrogen Receptor and Progesterone Receptor Status for Breast Cancer
HER2 Overexpression and Herceptin and Tykerb
Epidermal Growth Factor Receptor (EGFR)
KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
BRAF Mutations and Cancer Therapy
UGT1A1 Genetic Variants
5-Flurouracil Therapy
PIK3CA Genetic Variation
KIF6 Genetic Variation
ALK Genetic Variation
CHAPTER FIVE: DIAGNOSTIC PRODUCTS
PCR-based assays
Single nucleotide polymorphism (SNP) genotyping
Next-gen sequencing
LDTs reign
Miniaturization and Multiplexed Assays
Multi-Gene/Biomarker Tests in Oncology
Mass Spectroscopy
Role of Nanobiotechnology
Proteomics and Biomarker Detection
Molecular Imaging and Personalized Medicine
Information Technology
CHAPTER SIX: MARKET ANALYSIS
Background
Worldwide Opportunities for Personalized Medicine Diagnostics
The United States
Europe
Japan
ROW
Agreements between Pharmaceutical and Diagnostic Companies
Agreements between IVD companies and CLIA labs
Major Companies and Labs
The Market for Personalized Medicine in Cancer Management
Tissue-based Tests
Blood Markers
Circulating Tumor Cells
The Market for Personalized Medicine in Infectious Diseases
HIV
HBV
HCV
Hospital Acquired Infections
The Market for Personalized Medicine in Coagulation Therapy
Warfarin
Platelet Function
The Market for Personalized Medicine in Autoimmune Diseases
The Market for Personalized Medicine in Cardiovascular Diseases
The Market for Personalized Medicine in CNS Disorders
The Market for Personalized Medicine in Diabetes
The Market for Personalized Medicine in Blood Transfusion Safety
The Market for Personalized Medicine in Nutrition and Beauty
CHAPTER SEVEN: CONCLUSIONS AND STRATEGIC IMPLICATIONS
CHAPTER EIGHT: COMPANY PROFILES
The Major IVD Companies
Abbott Diagnostics Beckman Coulter Inc. Becton, Dickinson and Company
bioMérieux Inc.
Celera Corporation
Cepheid
China Medical Technologies
Dako Denmark A/S
Fujirebio Diagnostics, Inc.
GE Healthcare
Gen-Probe Inc.
Immucor, Inc.
Luminex Corporation
PerkinElmer Inc.
Phadia AB
QIAGEN N.V.
Roche Diagnostics
Siemens Healthcare Diagnostics
Ventana Medical Systems Inc.
Wako Diagnostics
Participants
20/20 GeneSystems, Inc.
23andMe
Accumetrics
AdvanDx, Inc.
Affymetrix, Inc.
Agendia BV
Almac Diagnostics
AltheaDx, Inc.
Ambry Genetics
Arrayit Corporation
ARUP Laboratories
AssureRx Health, Inc.
Asuragen, Inc.
Autogenomics Inc.
BG Medicine, Inc.
Biocare Medical, LLC
Biocartis SA
Biocept, Inc.
BioCurex, Inc.
Biodesix, Inc.
BioReference Laboratories, Inc.
BioServe
bioTheranostics
Clarient Inc.
CombiMatrix Molecular Diagnostics, Inc.
Corgenix Medical Corporation
Cylex, Inc.
Dana Farber Cancer Institute
DeCode Genetics
DxS Ltd.
DxTerity Diagnostics Inc.
Enzo Clinical Labs
Epigenomics AG
Euroimmun AG
Genelex Corporation
Genomic Health, Inc.
Genoptix Medical Laboratory
Genzyme Genetics
Illumina Inc.
Interleukin Genetics, Inc.
Ipsogen SA
Knome, Inc.
Lab21 Limited
Laboratory Corporation of America Holdings (LabCorp)
Life Technologies Corporation
Mayo Medical Laboratories
MDxHealth SA
Monogram Biosciences, Inc.
Myriad Genetics, Inc.
Nanosphere, Inc.
Navigenics
Pathway Genomics
Pathwork Diagnostics, Inc.
Power3 Medical Products, Inc.
Precision Therapeutics
Predictive Biosciences
Progenika Inc.
Prometheus Laboratories Inc.
Quest Diagnostics Incorporated
Response Genetics, Inc.
Rosetta Genomics
Rules-Based Medicine, Inc.
Saladax Biomedical, Inc.
Sequenom, Inc.
TGen (The Translational Genomics Research Institute)
TrimGen Corporation
TrovaGene, Inc.
Veridex, LLC
Vermillion Inc.
Virco BVBA
XDx, Inc.
The Newcomers
Abkine Pharmaceuticals
Accelerated Medical Diagnostics, LLC
Advanced Biological Laboratories
Affomix Corporation
Ahram Biosystems, Inc.
Alacris Theranostics GmbH
Amoy Diagnostics Co. Ltd.
ApoCell, Inc.
Atossa Genetics, Inc.
Augurex Life Sciences Corp.
Biofortuna Ltd.
Biomarker Factory, The
BioMarker Strategies
Biomedical Diagnostics
BlackBio S.L.
Bostwick Laboratories
Cancer Genetics, Inc.
Cancer Treatment Centers of America
CancerGuide Diagnostics, Inc.
CardioDx, Inc.
Caris Life Sciences
Chronix Biomedical
Crescendo Bioscience, Inc.
Critical Diagnostics
Curidium Medica Limited
CvergenX
DermaGenoma, Inc.
DiaTech Oncology
Eutropics Pharmaceuticals
Everist Genomics
Evotec AG
Exosome Diagnostics Inc.
Foundation Medicine Inc.
GeneNews Limited
Genetic Technologies Limited
GenMark Diagnostics Inc.
Genomas
Genomind, LLC
GenoVive LLC
GMS Biotech
Inostics GmbH
Insight Genetics
IntegraGen SA
IRIS International, Inc.
Iverson Genetic Diagnostics, Inc.
Linkage Biosciences, Inc.
Med BioGene, Inc.
Medco Health Solutions Inc.
Metamark Genetics, Inc.
Mira Dx
Molecular Response
MolecularMD Corp.
Nanostring Technologies, Inc.
NaturalNano, Inc.
NewGene
NobleGen Biosciences
Nodality Inc.
Novartis Molecular Diagnostics
Nuvera Biosciences, Inc.
On-Q-ity
Orion Genomics
OvaGene Oncology, Inc.
Pacific Edge Biotechnology Limited
Pathogenica
Pharmigene
Pinpoint Genomics, Inc.
Population Diagnostics, Inc.
Proctor & Gamble
Psynomics Incorporated
Radient Pharmaceuticals Corporation
ScreenCell
Scripps Health
Seegene Inc.
Signal Genetics
Signature Diagnostics AG
Sirius Genomics
Skyline Diagnostics B.V.
Spartan Bioscience Inc.
SureGene, LLC
TcLand Expression SA
Transgenomic, Inc.
ViennaLab Diagnostics GmbH
Information Technology Specialists
CLC bio
CollabRx
Definiens
Dell Healthcare and Life Sciences
DNA Direct
GenomeQuest Inc.
HolGenTech Inc.
IDBS
MediSapiens Ltd.
Partners HealthCare Center for Personalized Genetic Medicine
Selventa
Sophic Systems Alliance
LIST OF TABLES
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1 Exchange Rate Fluctuations, 2005-2010
Table 1-2 Worldwide Personalized Medicine Test Sales, 2011-2016
CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”
Table 3-1 Selected Company Sponsored Certified Labs
Table 3-2 Proposed Palmetto non-coverage tests
Table 3-3 Selected LDT Companies Cited by the FDA
Table 3-4 Selected POC-appropriate Systems
CHAPTER FOUR: DISEASE TARGETS
Table 4-1 Selected Drug/Biomarker Targets in the U.S.
Table 4-2 Selected drugs that require PMx testing in Europe
Table 4-3 Selected Commercial CYP450 Warfarin Tests
Table 4-4 Selected drugs associated with CYP450 metabolism
Table 4-5 Selected innovations in EFGR tests
Table 4-6 Selected KRAS test innovations
Table 4-7 Selected BRAF gene test innovations
Table 4-8 Selected PIK3CA mutation test innovations
Table 4-9 Selected Innovations in CTC Systems
Table 4-10 Selected Live Cell Assays
CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES
Table 5-1 Selected Novel Nucleic Acid Testing Platforms, 2008-2011
Table 5-2 Major Sequencing Platforms
Table 5-3 Selected innovations in sequencing
Table 5-4 Selected Company Sponsored Certified Labs
Table 5-5 Selected LDT Service Provider Revenues, 2007-2011
Table 5-6 Selected PMx tests using microarrays
Table 5-7 Selected Gene Expression Tests
Table 5-8 Selected innovations in mass spectroscopy for personalized medicine
Table 5-9 Selected novel biomarkers under investigation
Table 5-10 Selected Innovations in Protein Biomarkers
Table 5-11 Selected companies involved in chromosomal analysis of cells
Table 5-12 Selected test digital platform innovations
Table 5-13 Selected blood-based tests in personalized medicine
Table 5-14 IT solutions for personalized medicine
CHAPTER SIX: MARKET ANALYSIS
Table 6-1 Worldwide Commercial Personalized Medicine Test Sales, by category
Table 6-2 Market Penetration Of PMx Tests, by geographic area, 2011-2016
Table 6-3 Selected Agreements between IVD Companies and Lab Services
Table 6-4 Worldwide Sales of PMx Tests for Cancer, by category, 2011-2016
Table 6-5 Major protein and molecular markers used in tissue staining
Table 6-6 Selected Pharmacodiagnostic Histology Tests
Table 6-7 Selected chromosome-based cancer tests and services
Table 6-8 Selected HPV tests
Table 6-9 Selected Tumor Marker Innovations, 2008-2011
Table 6-10 Selected Innovations in Molecular PMx Tests for Cancer
Table 6-11 PMx Test Sales for Infectious Diseases, worldwide, 2011-2016
Table 6-12 Selected PMx tests for infectious diseases
Table 6-13 Selected commercial MDR-TB test kits
Table 6-14 Selected molecular PMx coagulation tests
Table 6-15 Selected innovations in PMx testing for autoimmune diseases
Table 6-16 Selected IVD markers of CVD
Table 6-17 Worldwide PMx product sales for CVD, by category, 2011-2016
Table 6-18 Selected Cardiac Marker Innovations, 2008-2011
Table 6-19 Selected innovations in genetic tests for CVD
Table 6-20 Selected innovations in personalized tests for CNS diseases
CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1 Exchange Rate Fluctuations, 2005-2010
Table 1-2 Worldwide Personalized Medicine Test Sales, 2011-2016
CHAPTER THREE: STRATEGIC ISSUES: THE “COMMERCIALIZATION CONDUNDRUM”
Table 3-1 Selected Company Sponsored Certified Labs
Table 3-2 Proposed Palmetto non-coverage tests
Table 3-3 Selected LDT Companies Cited by the FDA
Table 3-4 Selected POC-appropriate Systems
CHAPTER FOUR: DISEASE TARGETS
Table 4-1 Selected Drug/Biomarker Targets in the U.S.
Table 4-2 Selected drugs that require PMx testing in Europe
Table 4-3 Selected Commercial CYP450 Warfarin Tests
Table 4-4 Selected drugs associated with CYP450 metabolism
Table 4-5 Selected innovations in EFGR tests
Table 4-6 Selected KRAS test innovations
Table 4-7 Selected BRAF gene test innovations
Table 4-8 Selected PIK3CA mutation test innovations
Table 4-9 Selected Innovations in CTC Systems
Table 4-10 Selected Live Cell Assays
CHAPTER FIVE: DIAGNOSTIC TECHNOLOGIES
Table 5-1 Selected Novel Nucleic Acid Testing Platforms, 2008-2011
Table 5-2 Major Sequencing Platforms
Table 5-3 Selected innovations in sequencing
Table 5-4 Selected Company Sponsored Certified Labs
Table 5-5 Selected LDT Service Provider Revenues, 2007-2011
Table 5-6 Selected PMx tests using microarrays
Table 5-7 Selected Gene Expression Tests
Table 5-8 Selected innovations in mass spectroscopy for personalized medicine
Table 5-9 Selected novel biomarkers under investigation
Table 5-10 Selected Innovations in Protein Biomarkers
Table 5-11 Selected companies involved in chromosomal analysis of cells
Table 5-12 Selected test digital platform innovations
Table 5-13 Selected blood-based tests in personalized medicine
Table 5-14 IT solutions for personalized medicine
CHAPTER SIX: MARKET ANALYSIS
Table 6-1 Worldwide Commercial Personalized Medicine Test Sales, by category
Table 6-2 Market Penetration Of PMx Tests, by geographic area, 2011-2016
Table 6-3 Selected Agreements between IVD Companies and Lab Services
Table 6-4 Worldwide Sales of PMx Tests for Cancer, by category, 2011-2016
Table 6-5 Major protein and molecular markers used in tissue staining
Table 6-6 Selected Pharmacodiagnostic Histology Tests
Table 6-7 Selected chromosome-based cancer tests and services
Table 6-8 Selected HPV tests
Table 6-9 Selected Tumor Marker Innovations, 2008-2011
Table 6-10 Selected Innovations in Molecular PMx Tests for Cancer
Table 6-11 PMx Test Sales for Infectious Diseases, worldwide, 2011-2016
Table 6-12 Selected PMx tests for infectious diseases
Table 6-13 Selected commercial MDR-TB test kits
Table 6-14 Selected molecular PMx coagulation tests
Table 6-15 Selected innovations in PMx testing for autoimmune diseases
Table 6-16 Selected IVD markers of CVD
Table 6-17 Worldwide PMx product sales for CVD, by category, 2011-2016
Table 6-18 Selected Cardiac Marker Innovations, 2008-2011
Table 6-19 Selected innovations in genetic tests for CVD
Table 6-20 Selected innovations in personalized tests for CNS diseases
